Adial Pharmaceuticals financials
$4.15+2.72%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$52.0M | -$2.0M | -$1.9M | -$1.8M | -$1.9M | -$2.3M | -$1.9M | -$2.2M | -$2.3M | -$1.8M | -$1.8M | -$1.4M |
| Net income | -$52.0M | -$2.0M | -$2.0M | -$1.8M | -$2.0M | -$2.2M | -$2.1M | -$2.2M | -$2.5M | -$6.5M | -$1.9M | -$1.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-11.25 | $-1.48 | — | $-2.00 | $-4.61 | $-8.52 | $-8.05 | $-9.50 | $-14.75 | $-54.75 | $-20.60 | $-29.50 |
| EBITDA | -$52.0M | -$2.0M | -$1.9M | -$1.8M | -$1.9M | -$2.3M | -$1.9M | -$2.2M | -$2.3M | -$1.8M | -$1.8M | -$1.4M |
| Operating cash flow | -$6.4M | -$1.6M | -$1.3M | -$1.8M | -$1.7M | -$1.6M | -$1.5M | -$1.7M | -$2.1M | -$1.6M | -$1.2M | -$1.4M |
| Free cash flow | -$6.4M | -$1.6M | -$1.3M | -$1.8M | -$1.7M | -$1.6M | -$1.5M | -$1.7M | -$2.1M | -$1.6M | -$1.2M | -$1.4M |
| Diluted shares | 4.6M | 1.4M | — | 0.9M | 0.4M | 0.3M | 0.3M | 0.2M | 0.2M | 0.1M | 0.1M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $28.7M | $4.6M | $5.9M | $4.6M | $5.9M | $2.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $29.1M | $5.2M | $6.7M | $5.7M | $6.8M | $3.5M |
| Total liabilities | $28.9M | $1.5M | $1.4M | $1.2M | $1.2M | $1.3M |
| Shareholders' equity | -$38.4M | $3.7M | $5.3M | $4.5M | $5.6M | $2.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology